Latest News

Surgery Shows Longer-Term Benefits for Dupuytren Contracture


 

FROM ANNALS OF INTERNAL MEDICINE

A First for the Comparison

Dawn LaPorte, MD, a hand surgeon at Johns Hopkins Medicine in Baltimore, Maryland, who also was not part of the study, says although surgery was thought to have better long-term success rates, this is the first time the data have been able to show that at 2 years.

She added that the results are particularly striking because the endpoint was a 50% release when surgeons hope for a complete release. Even with the 50% release outcome at 2 years, surgery had better success.

She noted that the authors plan to look at outcomes at 5 and 10 years, but, she says, “the fact that surgery is already significantly better at 2 years really says a lot.”

Treatments Have Tradeoffs

She says the conclusions may change the discussions physicians have with patients.

Collagenase injections are an office procedure, and there’s no anesthesia. “There’s usually no lost time from work, and they can use their hand pretty normally the following day,” Dr. LaPorte says. One downside, compared with surgery, is that there may be a more frequent recurrence rate. Patients may have a skin tear that usually heals over a couple of weeks, she added.

Additionally, “the collagenase drug is very expensive,” she notes, so preapproval is important so that the patient doesn’t have to pay out of pocket.

Needle fasciotomy can also be done in the office without anesthesia. There’s less time off work than with surgery.

“With both that and the injection, they should see release of the contracture right away,” Dr. LaPorte says, but the concern is a quicker recurrence rate.

While surgery isn’t a cure, she says, and there is a lower recurrence rate, it typically means time off work, anesthesia, and an incision to heal, and may mean postoperative therapy.

The study was funded by the Research Council of Finland. Disclosures are available with the full text.

Dr. LaPorte and Dr. Scott report no relevant financial relationships.

Pages

Recommended Reading

FDA OKs first ustekinumab biosimilar
MDedge Rheumatology
Strength training promotes knee health, lowers OA risk
MDedge Rheumatology
First referral guide issued for axial spondyloarthritis
MDedge Rheumatology
Rheumatology Match Day results for 2024 follow trends of past years
MDedge Rheumatology
Teen and young adult rheumatology patients report gaps in sexual health counseling
MDedge Rheumatology
Novel Solutions Needed to Attract Residents to Pediatric Rheumatology
MDedge Rheumatology
Paget Disease of the Bone Progression Halted With Genetic Screening, Targeted Treatment
MDedge Rheumatology
Chronic Fatigue Syndrome and Fibromyalgia: A Single Disease Entity?
MDedge Rheumatology
Corticosteroid Injections Don’t Move Blood Sugar for Most
MDedge Rheumatology
Proinflammatory Diet May Prompt Worse Pain Course in Knee OA
MDedge Rheumatology